CareDx (CDNA) Tops Q3 EPS by 39c, Beats on Revenue; Offers FY24 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance
November 4, 2024 4:05 PM ESTBRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) today announced financial results for the third quarter ended September 30, 2024.
Third Quarter 2024 Financial Highlights
Total revenue of $82.9 million increased 23% year-over-year Testing Services volume of 44,600 tests increased 16% year-over-year GAAP net loss of $7.4 million, non-GAAP net income of $8.0 million, and positive adjusted EBITDA of $6.9 million, a significant improvement from the third quarter 2023 Cash flow from operations of $12.5 million. Cash, cash equivalents, and marketable securities of $241 million, with no debt Raised annual revenue guidance to $327 to $331 million... More